Latest news with #imaging
Yahoo
3 days ago
- Business
- Yahoo
Riley Maintains ‘Buy' Rating on Lantheus Holdings, Inc. (LNTH); Lowers PT
Lantheus Holdings, Inc. (NASDAQ:LNTH) is one of the best stocks for a . A pharmacist in their lab coat preparing a drug-free nasal spray for distribution. Riley lowered its price target on LNTH from $122 to $109, maintaining a 'Buy' rating on June 24, 2025. This reduction follows the company's profitability pressures despite the top-line growth. On one hand, the revenue for Q1 2025 rose 0.8% YoY, while on the other hand, adjusted earnings per share (EPS) fell by 9.5% to $1.53 per share. Meanwhile, Lantheus Holdings, Inc. (NASDAQ:LNTH) is making strategic moves amid margin pressures. Its strategic moves include the acquisition of Evergreen Theragnostics and Life Molecular Imaging. Looking ahead, the company plans to divest from its SPECT segment to SHINE Technologies. These initiatives highlight the company's efforts to reinforce its PET-focused pipeline and strengthen its long-term position in radiotherapeutics. Lantheus Holdings, Inc. (NASDAQ:LNTH) is a developer of radiopharmaceutical and imaging solutions. Its portfolio consists of PET imaging agents like PYLARIFY, ultrasound contrast DEFINITY, and AI-driven imaging software. While we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: 10 Best Marketing Stocks to Buy Right Now and 10 Best Cybersecurity Stocks to Invest in Under $20. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Riley Maintains ‘Buy' Rating on Lantheus Holdings, Inc. (LNTH); Lowers PT
Lantheus Holdings, Inc. (NASDAQ:LNTH) is one of the best stocks for a . A pharmacist in their lab coat preparing a drug-free nasal spray for distribution. Riley lowered its price target on LNTH from $122 to $109, maintaining a 'Buy' rating on June 24, 2025. This reduction follows the company's profitability pressures despite the top-line growth. On one hand, the revenue for Q1 2025 rose 0.8% YoY, while on the other hand, adjusted earnings per share (EPS) fell by 9.5% to $1.53 per share. Meanwhile, Lantheus Holdings, Inc. (NASDAQ:LNTH) is making strategic moves amid margin pressures. Its strategic moves include the acquisition of Evergreen Theragnostics and Life Molecular Imaging. Looking ahead, the company plans to divest from its SPECT segment to SHINE Technologies. These initiatives highlight the company's efforts to reinforce its PET-focused pipeline and strengthen its long-term position in radiotherapeutics. Lantheus Holdings, Inc. (NASDAQ:LNTH) is a developer of radiopharmaceutical and imaging solutions. Its portfolio consists of PET imaging agents like PYLARIFY, ultrasound contrast DEFINITY, and AI-driven imaging software. While we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: 10 Best Marketing Stocks to Buy Right Now and 10 Best Cybersecurity Stocks to Invest in Under $20. Disclosure: None.
Entrepreneur
5 days ago
- Business
- Entrepreneur
AMD India Funds Semiconductor Startup AAGYAVISION
The start-up is developing advanced imaging and sensing technologies using semiconductors, radar systems, and AI. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. AMD India has announced a new collaboration with the Foundation for Science Innovation and Development (FSID), an incubator affiliated with the Indian Institute of Science (IISc), Bengaluru, to support India's growing semiconductor ecosystem. As part of this initiative, AMD will provide a grant under its CSR program to AAGYAVISION, a deep-tech start-up incubated at FSID. The start-up is developing advanced imaging and sensing technologies using semiconductors, radar systems, and AI. "At AMD, we believe true innovation stems from collaboration and a strong ecosystem," said Jaya Jagadish, Country Head, AMD India. "By supporting start-ups like AAGYAVISION, we reaffirm our commitment to nurturing deep-tech entrepreneurship in India. Our goal is to help build technologies that truly make a difference." AAGYAVISION offers a full-stack radar solution including a custom-designed chip, radar hardware, and AI-powered algorithms for real-time control and signal analysis. Their technology enables high-resolution, all-weather, multi-band radars ideal for civilian security and future 6G smart infrastructure. "India is building a world-class semiconductor ecosystem," said Professor B Gurumoorthy, Director, FSID. "We are proud to support ventures like AAGYAVISION that align with the nation's semiconductor mission." The radar system is based on Frequency-Modulated Continuous Wave (FMCW) technology, developed after over seven years of research at IISc. It offers high precision, low power consumption, and cost-effective edge sensing solutions. "We are grateful to AMD for this support," said Suchismita Banerjee, CEO of AAGYAVISION. "Working with AMD mentors will allow us to further enhance our edge computing capabilities and bring our radar-on-chip solution closer to commercialization." With this backing, AAGYAVISION aims to soon launch its next-generation radar solution, setting new benchmarks in imaging, sensing, and smart connectivity.
Associated Press
11-06-2025
- Business
- Associated Press
Conavi Medical to Present at the Life Sciences Virtual Investor Forum June 12th
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) ('Conavi Medical' or the 'Company'), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that Thomas Looby, CEO, will present live at the Life Sciences Virtual Investor Forum hosted by on June 12th, 2025 DATE: June 12th TIME: 2:00 PM ET LINK: REGISTER HERE This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at . Recent Company Highlights Upsized $20 million CAD financing led by U.S. institutional investors is expected to support finalizing product development of the next-generation Novasight Hybrid system, submit for regulatory clearance and enable commercial launch New U.S. intracoronary imaging guidelines from the American College of Cardiology and recent peer-reviewed research strongly validate Novasight's unique value proposition U.S. FDA 510(k) submission remains on track for calendar Q3 2025 About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare. For more information, visit . About Virtual Investor Conferences® Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. Forward-Looking Statements This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Conavi and its business, which may include, but are not limited to, statements with respect to the anticipated use of proceeds from the April 2025 public offering, Conavi's exposure to the U.S. investment community, the commercialization and development of the Novasight Hybrid System and the achievement and timeline of key milestones towards commercialization and development of the Novasight Hybrid System. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are 'forward-looking information or statements'. Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'anticipate', 'believe', 'plan', 'expect', 'intend', 'estimate' 'anticipate' or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the 'Risk Factors' section of the short form prospectus dated April 15, 2025 and the joint information circular of the Company dated August 30, 2024 (both of which are on the Company's profile at ). Although Conavi has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Conavi does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Contacts: Conavi Medical Stefano Picone Chief Financial Officer [email protected] (416) 483-0100 Virtual Investor Conferences John M. Viglotti SVP Corporate Services, Investor Access OTC Markets Group (212) 220-2221 [email protected]
New York Times
30-05-2025
- General
- New York Times
George E. Smith, Nobel Winner Who Created a Digital Eye, Dies at 95
George E. Smith, who won the Nobel Prize in Physics for inventing a revolutionary imaging device that has not only allowed scientists see the universe more clearly but has also made it possible for hundreds of millions of people to record every birthday and vacation for posterity, died on Wednesday at his home in Barnegat Township, N.J. He was 95. His death was confirmed by his daughter Lauren Lanning. It was while he was working at Bell Laboratories in 1969 that Dr. Smith and a colleague, Willard S. Boyle, came up with the idea for what is known as the charge-coupled device, or CCD — a technology that is an essential component of nearly every telescope, medical scanner, photocopier and digital camera in use today. Their work helped build 'the foundation to our modern information society,' Gunnar Oquist, the Nobel academy's secretary general, said when it was announced that Dr. Smith and Dr. Boyle would share the 2009 prize for physics. (They split the award with Charles K. Kao, who was recognized for work that resulted in the development of fiber-optic cables.) Dr. Smith and Dr. Boyle had been trying to create better memory storage for computers when the idea for the CCD arose. They thought the photoelectric effect — which Einstein had explained, an explanation that won him a 1921 Nobel Prize — might offer a solution. The photoelectric phenomenon occurs when electromagnetic radiation, such as light, hits a metal surface, dislodging electrons from atoms and causing a current to flow through the metal. The device that Dr. Smith and Dr. Boyle created employs rows of tiny capacitors to store and transfer the electrical charge — essentially capturing light — and uses the information to construct an image. Want all of The Times? Subscribe.
